



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an Independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy

Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening

Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)
- [Endnotes](#)

Policy Number: 557

BCBSA Reference Number: 2.04.29

NCD/LCD: Decision Memo for Screening for Colorectal Cancer - Stool DNA Testing (CAG-00440N)

Related Policies

None

Policy¹

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members

CologuardTM, a multitarget stool DNA test, is considered **MEDICALLY NECESSARY** as a colorectal cancer screening test for asymptomatic, average risk patients who meet all of the following criteria:

- Age 50 to 85 years, AND
- Asymptomatic (no signs or symptoms of colorectal disease including but not limited to lower gastrointestinal pain, blood in stool, positive guaiac fecal occult blood test or fecal immunochemical test), AND
- At average risk of developing colorectal cancer (no personal history of adenomatous polyps, colorectal cancer, or inflammatory bowel disease, including Crohn's Disease and ulcerative colitis; no family history of colorectal cancers or adenomatous polyps, familial adenomatous polyposis, or hereditary nonpolyposis colorectal cancer).

All other DNA analysis of stool samples as a screening technique for colorectal cancer, in both patients with average to moderate risk and patients considered at high risk for colorectal cancer, is **INVESTIGATIONAL**.

[Decision Memo for Screening for Colorectal Cancer - Stool DNA Testing \(CAG-00440N\)](#)

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	Prior authorization is not required .
Commercial PPO and Indemnity	Prior authorization is not required .
Medicare HMO Blue SM	Prior authorization is not required .
Medicare PPO Blue SM	Prior authorization is not required .

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The above **medical necessity criteria MUST** be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

CPT Codes

CPT codes:	Code Description
81528	Oncology (colorectal) screening, quantitative real-time target and signal amplification of 10 dna markers (kras mutations, promoter methylation of ndrg4 and bmp3) and fecal hemoglobin, utilizing stool, algorithm reported as a positive or negative result

DESCRIPTION

COLORECTAL CANCER

Several cellular genetic alterations have been associated with colorectal cancer (CRC). In the proposed multistep model of carcinogenesis, the tumor suppressor gene *p53* and the proto-oncogene *KRAS* are most frequently altered. Variants in adenomatous polyposis coli genes and epigenetic markers (eg, hypermethylation of specific genes) have also been detected. CRC is also associated with DNA replication errors in microsatellite sequences (termed microsatellite instability) in patients with Lynch syndrome (formerly known as hereditary nonpolyposis CRC) and in subgroups of patients with sporadic colon carcinoma. Tumor-associated gene variants and epigenetic markers can be detected in exfoliated intestinal cells in stool specimens. Because cancer cells are shed into stool, tests have been developed to detect these genetic alterations in the DNA from shed CRC cells isolated from stool samples.

REGULATORY STATUS

On August 12, 2014, Cologuard™ (Exact Sciences) was approved by the U.S. Food and Drug Administration (FDA) through the premarket approval process as an automated fecal DNA testing product (P130017). Cologuard™ is intended for the qualitative detection of colorectal neoplasia associated DNA markers and of occult hemoglobin in human stool. A positive result may indicate the presence of CRC or advanced adenoma and should be followed by diagnostic colonoscopy. Cologuard™ is indicated to screen adults of either sex, 50 years or older, who are at average risk for CRC. Cologuard™ is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.

Over the past several years, different stool DNA tests have been evaluated in studies, and some have been marketed. One previously marketed test, PreGen-Plus™ (LabCorp), tests for 21 different variants in

the *p53*, adenomatous polyposis coli, and *KRAS* genes; the BAT-26 microsatellite instability marker; and incorporates the DNA Integrity Assay (DIA®). PreGen-Plus™ has not been cleared by FDA. In January 2006, FDA informed LabCorp that PreGen-Plus™ may be subject to FDA regulation as a medical device. As a consequence, and as a result of studies showing better performance of other tests, this test is no longer offered. Another previously marketed test is called ColoSure™ (OncoMethylome Sciences; now MDxHealth), which detects aberrant methylation of the vimentin (*hV*) gene. This test was offered as a laboratory-developed test and is not subject to FDA regulation.

Summary

Detection of DNA abnormalities associated with colorectal cancer (CRC) in stool samples has been proposed as a screening test for CRC. This technology is another potential alternative to currently available screening approaches such as fecal occult blood testing, fecal immunochemical testing (FIT), and colonoscopy. The currently available stool DNA test combines FIT and DNA analysis and is referred to as FIT-DNA in this review.

For individuals who are asymptomatic and at average risk of CRC who receive FIT-DNA, the evidence includes a number of small studies comparing FIT-DNA (in early stages of development) with colonoscopy, 2 screening studies comparing the final version of the FIT-DNA (using colonoscopy as the reference standard), and modeling studies. Relevant outcomes are overall survival and disease-specific survival. The screening studies have reported that FIT-DNA has higher sensitivity and lower specificity than FIT. There are no studies directly assessing health outcomes such as overall survival or disease-specific survival. The test characteristics of FIT-DNA show the potential of the test to be an effective CRC screening test, but there is uncertainty about other aspects of it. The screening interval for the test has not been firmly established nor is there evidence on the adherence of the test at a recommended screening interval. Effective screening for CRC requires a screening program with established screening intervals and appropriate follow-up for positive tests. Clinical utility of FIT-DNA is based on modeling studies. These studies have demonstrated that the diagnostic characteristics of FIT-DNA are consistent with decreases in CRC mortality that are in the range of other accepted modalities. FIT-DNA every 3 years is less effective than most other accepted screening strategies, while FIT-DNA every year is close to the efficacy of colonoscopy every 10 years. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Policy History

Date	Action
1/2019	BCBSA National medical policy review. Description, summary and references updated. Policy statements unchanged.
1/2018	New references added from BCBSA National medical policy.
12/2016	New references added from BCBSA National medical policy.
1/2016	Clarified coding information.
10/2015	New medically necessary statement added for commercial plans. Effective 10/1/2015.
1/2015	CMS decision memo for screening for colorectal cancer - stool DNA testing (CAG-00440N) added. Clarified coding information. Effective 10/9/2014.
12/2014	New references added from BCBSA National medical policy.
2/2014	New references added from BCBSA National medical policy.
11/2011-4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.
7/2011	Reviewed - Medical Policy Group – Hematology and Oncology. No changes to policy statements.
3/21/2011	New policy describing ongoing non-coverage.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

References

1. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. *N Engl J Med*. Apr 3 2014;370(14):1287-1297. PMID 24645800
2. Ahlquist DA, Zou H, Domanico M, et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. *Gastroenterology*. Feb 2012;142(2):248-256; quiz e225-246. PMID 22062357
3. Ahlquist DA, Taylor WR, Mahoney DW, et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. *Clin Gastroenterol Hepatol*. Mar 2012;10(3):272-277 e271. PMID 22019796
4. Lidgard GP, Domanico MJ, Bruinsma JJ, et al. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. *Clin Gastroenterol Hepatol*. Oct 2013;11(10):1313-1318. PMID 23639600
5. Redwood DG, Asay ED, Blake ID, et al. Stool DNA Testing for screening detection of colorectal neoplasia in Alaska Native people. *Mayo Clin Proc*. Jan 2016;91(1):61-70. PMID 26520415
6. Barzi A, Lenz HJ, Quinn DI, et al. Comparative effectiveness of screening strategies for colorectal cancer. *Cancer*. May 01 2017;123(9):1516-1527. PMID 28117881
7. Johnson DH, Kisiel JB, Burger KN, et al. Multitarget stool DNA test: clinical performance and impact on yield and quality of colonoscopy for colorectal cancer screening. *Gastrointest Endosc*. Mar 2017;85(3):657-665.e651. PMID 27884518
8. Knudsen AB, Zauber AG, Rutter CM, et al. Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US Preventive Services Task Force. *JAMA*. Jun 21 2016;315(23):2595-2609. PMID 27305518
9. Berger BM, Schroy PC, 3rd, Dinh TA. Screening for colorectal cancer using a multitarget stool DNA test: modeling the effect of the intertest interval on clinical effectiveness. *Clin Colorectal Cancer*. Sep 2016;15(3):e65-74. PMID 26792032
10. Blue Cross Blue Shield Association Technology Evaluation Center. Special Report: Fecal DNA Analysis for Colorectal Cancer Screening. *TEC Assessment*. 2014;Volume 29:Tab 8.
11. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. *N Engl J Med*. Dec 23 2004;351(26):2704-2714. PMID 15616205
12. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. *CA Cancer J Clin*. May-Jun 2008;58(3):130-160. PMID 18322143
13. Qaseem A, Denberg TD, Hopkins RH, Jr., et al. Screening for colorectal cancer: a guidance statement from the American College of Physicians. *Ann Intern Med*. Mar 6 2012;156(5):378-386. PMID 22393133
14. Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. *Am J Gastroenterol*. Mar 2009;104(3):739-750. PMID 19240699
15. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Colorectal Cancer Screening. Version 1.2018.
https://www.nccn.org/professionals/physician_gls/pdf/colorectal_screening.pdf. Accessed October 17, 2018.
16. Rex DK, Boland CR, Dornitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. *Gastroenterology*. Jul 2017;153(1):307-323. PMID 28600072
17. Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. *CA Cancer J Clin*. Jul 2018;68(4):250-281. PMID 29846947

18. U. S. Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. *JAMA*. Jun 21 2016;315(23):2564-2575. PMID 27304597
19. Centers for Medicare & Medicaid Services (CMS). Decision Memo for Screening for Colorectal Cancer - Stool DNA Testing (CAG-00440N). 2014; <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=277> Accessed October 18, 2018.

Endnotes

¹ Based on Medicare Decision Memo for Screening for Colorectal Cancer - Stool DNA Testing (CAG-00440N)